Pentwater Capital Management LP Has Cut Its Holding in Esperion Therapeutics INC (ESPR) by $20.41 Million as Shares Rose

April 19, 2018 - By Louis Casey

Investors sentiment decreased to 1.33 in 2017 Q4. Its down 0.34, from 1.67 in 2017Q3. It turned negative, as 19 investors sold ESPR shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported. Sectoral Asset Mgmt Inc reported 0.19% stake. Amundi Pioneer Asset Management Inc invested in 0.02% or 238,384 shares. Goldman Sachs Gp has 0.01% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 331,076 shares. Bb Biotech Ag has invested 4.38% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Parkside Fincl Savings Bank holds 0.02% or 900 shares. Lord Abbett And Communication Ltd reported 0.04% stake. Financial Bank Of America Corporation De stated it has 42,927 shares or 0% of all its holdings. Jasper Ridge Ptnrs Ltd Partnership invested in 0.04% or 9,773 shares. Bb&T Securities Ltd Liability holds 4,000 shares or 0% of its portfolio. Millennium Mngmt Limited reported 387,947 shares. State Street reported 1.17M shares stake. Citigroup Incorporated invested in 0% or 65,752 shares. Kansas-based Creative Planning has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Eam Ltd reported 85,548 shares. Ascend Cap Ltd Liability Com holds 67,241 shares.

Matthew Halbower decreased its stake in Esperion Therapeutics Inc (ESPR) by 14% based on its latest 2017Q4 regulatory filing with the SEC. Pentwater Capital Management Lp sold 313,969 shares as the company’s stock rose 22.41% while stock markets declined. The hedge fund run by Matthew Halbower held 1.93M shares of the health care company at the end of 2017Q4, valued at $127.02M, down from 2.24M at the end of the previous reported quarter. Pentwater Capital Management Lp who had been investing in Esperion Therapeutics Inc for a number of months, seems to be less bullish one the $1.97B market cap company. The stock decreased 1.07% or $0.8 during the last trading session, reaching $74.16. About 365,402 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since April 19, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Pentwater Capital Management Lp, which manages about $5.28 billion and $15.03B US Long portfolio, upped its stake in Synchrony Financial (Call) by 80,000 shares to 3.33M shares, valued at $128.39M in 2017Q4, according to the filing. It also increased its holding in Time Warner Inc (Put) by 4.12M shares in the quarter, for a total of 9.23 million shares, and has risen its stake in Vmware Inc (Put).

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on May, 3. They expect $-1.56 EPS, up 13.33 % or $0.24 from last year’s $-1.8 per share. After $-1.44 actual EPS reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 8.33 % negative EPS growth.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 11 analysts covering Esperion (NASDAQ:ESPR), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Esperion had 15 analyst reports since November 22, 2017 according to SRatingsIntel. The rating was upgraded by Bank of America on Friday, January 5 to “Buy”. The stock has “Buy” rating by Northland Capital on Wednesday, November 22. The company was maintained on Wednesday, February 21 by UBS. The stock has “Buy” rating by Cowen & Co on Tuesday, March 27. Chardan Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Tuesday, March 27 with “Neutral” rating. Stifel Nicolaus maintained it with “Buy” rating and $105.0 target in Monday, January 15 report. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Buy” rating by Needham on Thursday, December 14. The rating was maintained by UBS with “Buy” on Wednesday, January 17. JP Morgan maintained it with “Neutral” rating and $65 target in Wednesday, February 21 report. As per Monday, January 22, the company rating was downgraded by Citigroup.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.